In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials

Abstract excerpt

Clostridioides difficile is a bacterial pathogen responsible for significant morbidity and mortality across the globe. Current therapies based on broad-spectrum antibiotics have some clinical success, but approximately 30% of patients have relapses, presumably due to the continued perturbation to the gut microbiota. Here, we show that phages can be engineered with type I CRISPR-Cas systems and modified to reduce...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bacteriophages and microbial interactions
• Share to Clostridium difficile and Clostridium perfringens research
• Share to Viral gastroenteritis research and epidemiology